NAPIGEN is a biotech company that aims to harness the power of mitochondria by use of its unique genome editing tools. NAPIGEN's proprietary technology provides business opportunities in human healthcare, industrial biotechnology and agriculture. The company's first business target is to address the food security needs of our society in view of the dramatic population increase expected this century. NAPIGEN's technology enables the creation of plants designed to produce highly desirable non-GMO hybrid seeds. The company's first target crop plants are wheat and rice, which are the gain crops most planted and consumed by humans. The hybrid vigor created by NAPIGEN is expected to provide transformative increases in crop yields. NAPIGEN team members have extensive experience in biotech and agricultural R&D and business management gained at multinational agricultural seed companies such as DuPont and Monsanto.